Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.

Journal of medical genetics - 1 Sept 2014

Evans D Gareth, Harkness Elaine, Lalloo Fiona, Howell Anthony

Abstract excerpt

BACKGROUND: The risks of breast cancer associated with BRCA1 and BRCA2 mutations vary considerably across studies but few have assessed prospective risks, which are likely to provide more reliable risk estimates for women undergoing presymptomatic testing. METHODS: Prospective breast cancer risks were assessed in 254 unaffected women with BRCA1 mutations and 238 with BRCA2 mutations. Rates of breast cancer were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asymptomatic Diseases
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Kaplan-Meier Estimate

Share to Risk Assessment

Share to United Kingdom

Source

Identifiers

PMID: 25053764
DOI: 10.1136/jmedgenet-2014-102336

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.PMID 25053764Read ↗

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.Semantic proximity Read ↗

Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?Semantic proximity Read ↗

Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers.Semantic proximity Read ↗

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK.Semantic proximity Read ↗

Cancer risks among BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.Semantic proximity Read ↗

Assessing the effectiveness of NICE criteria for stratifying breast cancer risk in a UK cohort.Semantic proximity Read ↗

Clinical outcome and service implications of screening women at increased breast cancer risk from a family history.Semantic proximity Read ↗

Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.Semantic proximity Read ↗

Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Semantic proximity Read ↗

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.